Lyon Street Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Lyon Street Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-42,396	Closed	-$545K	–	64
2019 Q1	$545K	Sell	42,396 -720,545	-94%	-$8.15M	1.68%	35
2018 Q4	$7.25M	Sell	762,941 -688,759	-47%	-$8.93M	7.29%	2
2018 Q3	$24.1M	Sell	1,451,700 -19,818	-1%	-$318K	15.01%	1
2018 Q2	$23.6M	Buy	1,471,518 +230,225	+19%	+$4.11M	8.4%	3
2018 Q1	$19M	Buy	1,241,293 +412,203	+50%	+$6.43M	6.12%	3
2017 Q4	$12.9M	Buy	829,090 +287,628	+53%	+$3.85M	4.31%	4
2017 Q3	$6.01M	Buy	541,462 +415,867	+331%	+$3.91M	2.32%	15
2017 Q2	$1.16M	Buy	+125,595	New	+$1.05M	0.46%	48

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Lyon Street Capital's STML Position: Q2 2019 in Review

Lyon Street Capital sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 42,396 shares — an estimated $545K sold.

Lyon Street Capital first reported a position in STML in Q2 2017 and held it in 8 quarters. The position peaked at $24.1M in Q3 2018. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

Lyon Street Capital reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Lyon Street Capital sold 42,396 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $545K.
Lyon Street Capital first reported a position in Stemline Therapeutics, Inc. in Q2 2017 and held it in 8 quarters.
Lyon Street Capital's Stemline Therapeutics, Inc. position peaked at $24.1M in Q3 2018.
96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Lyon Street Capital's 13F filing for Q2 2019, filed 14 Aug 2019.